Strategic partnerships EBS has established collaborations with leading OTC consumer health companies, the world’s largest CPG company, and a top global functional beverage brand, signaling strong market validation and multiple potential distribution channels for new functional ingredients and APIs.

Clinical evidenced Commercialized product enterade Advanced Oncology formula is clinically proven to reduce chemotherapy and radiation side effects, with broad patient exposure (over 40,000). This provides a compelling case study for entering adjacent GI and oncology support categories.

IBS opportunity Recent launches of medical foods for IBS-D and GI symptom management create near-term cross-sell potential into digestive health, caregiver networks, and specialty retailers seeking IBS supportive products.

Patent defense Active European patent defense indicates a focus on protecting IP in key markets, suggesting opportunities to align with partners seeking safeguarded, differentiated ingredients and to accelerate regional go-to-market strategies.

Discovery edge Proprietary platform for small molecule amino acid combinations that modulate epithelial transmembrane proteins offers a unique value proposition to form strategic alliances with ingredient manufacturers, pharma clients, and contract development organizations aiming to enhance signaling-based health outcomes.